At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 9 enrolled
Drug / intervention
Ranibizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)
In Brief
A Phase 1 clinical trial evaluating Ranibizumab for Corneal Neovascularization. Completed, enrolled 9 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the effectiveness and safety of ranibizumab (Lucentis) in treatment of corneal neovascularization.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCorneal Neovascularization
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2008
First PostedMay 2008
Primary CompletionSep 2009
Study CompletionSep 2010
TodayJul 2026
First PostedMay 21, 2008
Enrollment StartApr 1, 2008
Primary CompletionSep 1, 2009
Study CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 18.1 years ago
Interventions
Ranibizumabdrug
10 Patients will receive treatment (Ranibizumab)